Background
==========

Despite convincing evidence of heritable susceptibility to acute coronary syndromes (ACS), including unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI),\[[@B1]\] most common genetic variants have yet to be validated conclusively as ACS risk factors. \[[@B2]-[@B4]\] We recently reported an attempt to validate putative cardiac risk factors,\[[@B5]\] all of which had been previously published in significant association with ACS or atherosclerosis, finding that only one pre-specified genetic risk genotype, homozygosity for the -455 A/G promoter variant in B-fibrinogen, could be replicated in our sample of 811 ACS cases and 650 controls. We concluded that our results did not support previous hypotheses generated by the candidate gene approach to ACS and that better study designs and unbiased screening approaches, such as whole genome association studies that have implicated 5 variants in the 9p21 region as ACS susceptibility factors,\[[@B6],[@B7]\] would be needed.

However, it is not yet known if candidate gene variants, including those in the 9p21 region, will affect prognosis following ACS. In theory, genes associated with the development of clinically significant atherosclerosis may also have a strong impact on subsequent prognosis after an ACS event has occurred. In particular, those who have already suffered ACS are at very high risk for suffering a subsequent fatal or nonfatal cardiac event, due not only to post-ACS physiological vulnerability, but also to the genetic and environmental risk factor profiles that led to the initial cardiac event. Against this backdrop of heightened risk, individual genetic effects may be markedly potentiated. With so many individuals currently surviving ACS events worldwide, there is an urgent need to identify improved methods for risk-stratifying patients\' post-ACS prognosis so that more aggressive efforts at secondary prevention or intracardiac defibrillator insertion can be considered. Moreover, the identification of clinically important genetic risks for an adverse outcome after an ACS can also identify new targets for potential intervention. Despite the importance of such investigations, few studies have examined the association of potential atherogenic risk factors on prognosis after an ACS. To stimulate this line of research, we have performed a longitudinal follow-up study to investigate the impact of 89 candidate gene variants on mortality following ACS.

Methods
=======

Candidate genes
---------------

Our search strategy for putative risk variants, along with a list of references for each variant, has been described previously,\[[@B5]\] and further details about each gene variant, including flanking DNA sequences, are available upon request from the authors. Reports were included if they contained a claim of a significant positive association, with an investigator-reported P value \< 0.05. Medline search terms included: \"gene, genetic, polymorphism, myocardial infarction, atherosclerosis, coronary heart disease, and coronary artery disease.\" In addition to the gene variants contained in our initial report, we genotyped the 5 variants in the 9p21 region that have recently been implicated in the occurrence of myocardial infarction. Overall, we identified, and successfully genotyped, 89 variants in 72 genes (or gene regions, in the case of 9p21, given that a causative mechanism has not yet been identified).

Study population and genotyping
-------------------------------

Eight hundred eleven self-reported white patients of European ancestry with ACS were identified from a consecutive series of patients presenting to two Kansas City, MO hospitals (Mid-America Heart Institute and Truman Medical Center), from March 2001 through June 2003. Standard definitions were used to diagnose ACS patients with either myocardial infarction or unstable angina.\[[@B8],[@B9]\] Individuals were monitored for incident deaths from any cause, as determined by periodic queries of the Social Security Administration Death Master File.\[[@B10]\] A minimum of 3 years of follow-up was available.

Genotyping was performed using the Sequenom MALDI-TOF (Matrix Assisted Laser Desorption-Ionization Time-of-Flight)\[[@B11],[@B12]\] system on whole genome amplified DNA.\[[@B13],[@B14]\] More extensive details of the cases and genotyping procedures have been recently described.\[[@B5]\]

Statistical Analysis
--------------------

Genotype distributions were examined for significant deviation (P \< 0.05) from Hardy-Weinberg equilibrium. PHASE Version 2.1 was used to estimate haplotype frequencies for *ALOX5AP*.\[[@B15],[@B16]\]

Initially, Kaplan-Meier survival analysis was performed for each variant (SAS 9.1, Research Triangle Park, NC). Cox regression models were then used to adjust positive associations for cardiac risk factors (age, sex, hypertension, congestive heart failure, diabetes), type of ACS (STEMI, NSTEMI, UA), and ACS treatments (aspirin and beta-blocker treatments provided in the first 24 hours, the use of angiography and revascularization, as well as quality of care indicators rendered at discharge (aspirin, beta-blocker, ACE inhibitor, and smoking cessation counseling)). We tested the proportional-hazards assumption for each covariate, by correlating the corresponding set of scaled Schoenfeld residuals with a suitable transformation of time based on the Kaplan-Meier estimate of the survival function. We applied the conservative Bonferroni correction in considering the overall statistical significance of results,\[[@B17]\] but we also simply compared the total number of all positive associations at the P \< 0.05 level to the expected number by chance, in 50,000 simulations (Resampling Stats, Inc., College Park, MD). An unexpected surplus of positive associations would imply that some of the tested polymorphisms may be truly associated with ACS.

Our sample had 93% power to detect an association, by the log rank test (P \< 0.05), for a hazard ratio of 2.5 or higher, given a frequent genotype (0.5), and 80% power to detect a hazard ratio of 3.3 or higher, given an infrequent genotype (0.1).\[[@B18]\] For weak effects (1.1--1.5 hazard ratio), power was limited, ranging from 5% (0.1 genotype frequency, 1.1 hazard) to 29% (0.5 genotype frequency, 1.5 hazard). Given that such genetic variants with modest effects may not reach the conventional statistical significance level of P \< 0.05, we sought to explore the possibility that null results might be related to lack of power (type II error), by examining the characteristics of the overall P value distribution. A Q-Q plot was performed, and supplemented with a simulation-based analysis. Random P values follow the Beta distribution. Hence, we subtracted random numbers between 0 and 1 (Beta distribution) from the observed P values, computed mean (observed-random) differences across all genetic variants, repeated this procedure 50,000 times, and plotted frequency histograms of the resulting 50,000 mean differences (Resampling Stats, Inc). In the presence of multiple *bona fide*genetic risk factors, but suboptimal power, the average mean P value difference (observed-random) would be less than zero. We initially included all P values from the individual Kaplan-Meier log-rank tests for all 89 genetic variants, and then sequentially removed those with the lowest P values until the remaining subset converged to a difference equal to zero, as would be expected for random variables showing no evidence of association with ACS.

Results
=======

The clinical characteristics of the 811 cases are described in Table [1](#T1){ref-type="table"}. The population of ACS cases included 308 (38%) STEMI, 284 (35%) NSTEMI, and 219 (27%) UA patients. A family history of coronary artery disease or myocardial infarction among first degree relatives was found in over half of cases. In addition, cardiac risk factor profiles were typical of a population with ACS, with over one half of patients having hypercholesterolemia and hypertension, a third with a history of smoking, and over one fifth with diagnosed diabetes. Previous revascularization had been performed in over a third of the ACS cases.

###### 

Characteristics of 811 white subjects with acute coronary syndrome at baseline

  **Characteristic**                 Male ACS Cases (N = 550)   Female ACS Cases (N = 261)
  ---------------------------------- -------------------------- ----------------------------
  Mean age in years (SD)             60.7 (12.5)                63.1 (13.2)
  Mean body mass index (SD)          29.1 (5.5)                 29.9 (6.9)
  Family history of CAD/MI (%)       279 (50.7)                 135 (51.7)
  Prior myocardial infarction(%)     142 (25.8)                 74 (28.4)
  Prior revascularization (%)        205 (37.3)                 83 (31.8)
  Congestive heart failure (%)       23 (4.2)                   18 (6.9)
  Hypertension (%)                   305 (55.5)                 182 (69.7)
  Diabetes Mellitus (%)              116 (21.1)                 77 (29.5)
  Hypercholesterolemia (%)           314 (57.1)                 162 (62.1)
  Postmenopausal (%)                 \--                        189 (68.6)
  College graduate (%)               166 (30.2)                 40 (15.3)
  Smoking \<30 days ago (%)          183 (33.3)                 85 (32.6)
  Alcohol frequency \> 1/month (%)   221 (40.2)                 38 (14.6)

Continuous variables are shown as mean (SD); categorical variables are number (%)

There were 90 deaths in the cohort, which was followed for a median time of 42.3 months. Risk factor data used in the multivariable models were missing for 2 individuals. Those individuals who died, as compared to survivors, did not differ significantly in sex (P = 0.33) or ACS type (P = 0.22). However, there were marked differences in overall cardiac risk factor profiles, as expected, with deceased patients having relatively advanced age, as well as more extensive cardiovascular comorbidity such as congestive heart failure (Table [2](#T2){ref-type="table"}).

###### 

Clinical characteristics of surviving and deceased patients in the follow-up cohort

  **Characteristic**                  Survivors     Deceased
  ----------------------------------- ------------- -------------
  Mean age in years (SD)‡             60.5 (12.5)   69.5 (11.6)
  Mean body mass index (SD)           29.4 (6.0)    28.8 (6.6)
  Family history of CAD/MI (%)        374 (52.0)    40 (44.4)
  Prior myocardial infarction(%)‡     176 (24.5)    40 (44.4)
  Prior revascularization (%)‡        241 (33.5)    47 (52.2)
  Congestive heart failure (%)‡       28 (3.9)      13 (14.4)
  Hypertension (%)\*                  423 (58.8)    63 (70.0)
  Diabetes Mellitus (%)‡              150 (20.9)    43 (47.8)
  Hypercholesterolemia (%)            419 (58.3)    57 (63.3)
  Postmenopausal (%)                  \--           \--
  College graduate (%)                185 (25.9)    19 (21.6)
  Smoking \<30 days ago (%)\*         249 (34.7)    18 (20.0)
  Alcohol frequency \> 1/month (%)‡   348 (55.8)    19 (24.4)

Continuous variables are shown as mean (SD); categorical variables are number (%) P \< 0.05, \*† P \< 0.01; ‡ P \< 0.001 for comparison between deceased and survivors

A total of 89 variants in 72 genes were genotyped. The overall genotype call rate for these variants was 98.5% (range 95.0--99.8%). Tests of Hardy Weinberg equilibrium revealed that 6 variants violated HWE at the P \< 0.05 level, which is not more than expected by chance (P = 0.29), given 89 chi-square tests (Table [2](#T2){ref-type="table"}).

The genotype distributions, numbers of deaths by genotypic category, and unadjusted P values for all 89 genetic variables are shown in Table [3](#T3){ref-type="table"}. Overall, there were 6 positive associations (P \< 0.05). Despite their established association with ACS, none of the 9p21 variants was associated with prognosis. Likewise, the -455 A/G promoter variant in B-fibrinogen, which had been weakly associated with ACS occurrence in our study population, was not associated with post-ACS mortality (P = 0.1). However, the *ACE1*I/I genotype was associated with a lower survival time (P = 0.04). In addition, the *APOA1*-75G/A polymorphism was associated with mortality (early death of a single individual with the rare A/A genotype). Survival time was relatively decreased among the 16 individuals with the rare A/A (glutamine homozygous) genotype of the *F7*Arg353Gln polymorphism (P = 0.01), with 5 deaths in this group. There was also excess mortality among heterozygotes for the *HFE*hemochromatosis-related allele (P = 0.04). In addition, individuals with the A/A genotype (lysine homozygotes) of the *ICAM1*Lys469Glu missense mutation had an increased mortality risk (P = 0.01). Finally, the strongest statistical association with post-ACS mortality was observed in *IRS1*arginine homozygotes, owing mainly to 2 early deaths among the 3 individuals with the rare A/A genotype in the Gly972Arg polymorphism; the deceased individuals were two males, aged 71 and 72 years, respectively, both of whom had extensive cardiac risk factor profiles. Heterozygotes had relatively low risk of death compared with homozygotes.

###### 

Kaplan-Meier analysis of mortality post-ACS for 89 genetic variants.

  Gene/SNP        Genotype   Total N   Deaths (%)   P      Gene             Genotype   Total N   Deaths (%)   P
  --------------- ---------- --------- ------------ ------ ---------------- ---------- --------- ------------ -------
  **ABCA1**       CC         191       18 (9.4)     0.50   **ICAM1**        AA         270       43 (15.9)    0.01
  -477C/T         CT         396       43 (10.9)           Lys469Glu        AG         379       32 (8.4)     
                  TT         188       25 (13.3)                            GG         145       14 (9.7)     
  **ABCA1**       AA         65        7 (10.8)     0.47   **IL1B**         CC         359       35 (9.8)     0.42
  Lys219Arg       AG         311       39 (12.5)           -511C/T          CT         311       33 (10.6)    
                  GG         416       41 (9.9)                             TT         82        12 (14.6)    
  **ACE1**        DD         233       28 (12)      0.04   **IL6**          CC         142       16 (11.3)    0.59
  I/D             DI         389       35 (9)              -174G/C          CG         386       39 (10.1)    
                  II         154       25 (16.2)                            GG         277       35 (12.6)    
  **ADD1**        GG         456       59 (12.9)    0.23   **IRS1**         AA         3         2 (66.7)     0.001
  Gly460Trp       GT         269       25 (9.3)            Gly972Arg        AG         84        4 (4.8)      
                  TT         26        2 (7.7)                              GG         704       81 (11.5)    
  **ADRB2**       CC         266       36 (13.5)    0.19   **ITGA2**        AA         123       17 (13.8)    0.46
  Glu27Gln\*      CG         358       33 (9.2)            Phe807Phe        AG         394       45 (11.4)    
                  GG         146       15 (10.3)                            GG         288       28 (9.7)     
  **ADRB2**       CC         789       89 (11.3)    0.41   **ITGB3**        CC         20        3 (15)       0.89
  Ile164Thr       CT         18        1 (5.6)             Leu33Pro         CT         188       21 (11.2)    
                  TT                                                        TT         588       64 (10.9)    
  **ADRB2**       AA         128       21 (16.4)    0.09   **LIPC**         CC         506       59 (11.7)    0.79
  Gly16Arg        AG         348       36 (10.3)           -514T/C          CT         256       26 (10.2)    
                  GG         309       31 (10)                              TT         42        5 (11.9)     
  **ADRB3**       CC         6         1 (16.7)     0.53   **LPL**          AG         29        3 (10.3)     0.93
  Arg64Trp        CT         111       16 (14.4)           Asp9Asn          GG         765       86 (11.2)    
                  TT         687       72 (10.5)                            GG                                
  **AGT**         CC         143       19 (13.3)    0.19   **LRP1**         AA         367       37 (10.1)    0.08
  Thr235Met       CT         387       48 (12.4)           Thr3261Thr       AG         330       46 (13.9)    
                  TT         272       23 (8.5)                             GG         85        5 (5.9)      
  **AGTR1**       AA         388       48 (12.4)    0.56   **LTA**          AA         394       44 (11.2)    0.52
  A1166C          AC         339       34 (10)             A252G            AG         327       38 (11.6)    
                  CC         79        8 (10.1)                             GG         81        6 (7.4)      
  **ALOX5AP**     A          123       12 (9.8)     0.61   **LTA**          AA         80        6 (7.5)      0.51
  HAP A           non-A      648       74 (11.4)           Thr26Asn         AC         331       39 (11.8)    
                                                                            CC         389       44 (11.3)    
  **ALOX5AP**     B          49        3 (6.1)      0.23   **MGP**          AA         308       36 (11.7)    0.81
  HAP B           non-B      722       83 (11.5)           Thr83Ala         AG         374       39 (10.4)    
                                                                            GG         123       15 (12.2)    
  **APOA1**       AA         23        2 (8.7)      0.91   **MGP**          AA         110       13 (11.8)    0.61
  C83T            AG         219       25 (11.4)           -7A/G            AG         368       37 (10.1)    
                  GG         532       59 (11.1)                            GG         328       40 (12.2)    
  **APOA1**       AA         1         1 (100)      0.01   **MMP3**         DD         194       20 (10.3)    0.22
  -75G/A          AG         10        1 (10)              indel            DI         386       37 (9.6)     
                  GG         784       87 (11.1)                            II         206       29 (14.1)    
  **APOE**        E4/E4      29        1 (3.5)      0.20   **MTHFR**        CC         350       39 (11.1)    0.53
  E2-3-4          Non-E4     771       87 (11.3)           Ala222Val        CT         341       40 (11.7)    
                                                                            TT         102       8 (7.8)      
  **APOE**        GG         194       25 (12.9)    0.42   **MTP**          GG         449       54 (12)      0.13
  -219T/G         GT         403       47 (11.7)           -493G/T          GT         297       33 (11.1)    
                  TT         206       18 (8.7)                             TT         59        2 (3.4)      
  **BDKRB2**      CC         263       25 (9.5)     0.40   **MTR**          AA         529       56 (10.6)    0.15
  -58C/T          CT         394       50 (12.7)           Asp919Gly        AG         239       32 (13.4)    
                  TT         145       14 (9.7)                             GG         34        1 (2.9)      
  **CCL11**       CC         539       64 (11.9)    0.76   **NPPA**         CC         22        2 (9.1)      0.65
  Thr23Ala        CT         239       24 (10)             Ter29ArgArg      CT         190       18 (9.5)     
                  TT         12        1 (8.3)                              TT         583       70 (12)      
  **CCR2**        AA         7         1 (14.3)     0.96   **OLR1**         CC         649       75 (11.6)    0.27
  Val64Ile        AG         116       12 (10.3)           Lys167Asn        CG         146       12 (8.2)     
                  GG         681       77 (11.3)                            GG         8         2 (25)       
  **CCR5**        II         631       72 (11.4)    0.51   *P22*-**PHOX**   CC         347       26 (7.5)     0.05
  Indel           ID         162       18 (11.1)           His72Tyr\*\*     CT         271       36 (13.3)    
                  DD         12        0 (0)                                TT         121       15 (12.4)    
  **CD14**        CC         204       25 (12.3)    0.22   **PAI1**         DD         249       32 (12.9)    0.33
  -159C/T         CT         395       47 (11.9)           indel            DI         398       38 (9.6)     
                  TT         204       16 (7.8)                             II         159       20 (12.6)    
  **CETP**        AA         168       13 (7.7)     0.13   **PECAM1**       CC         187       21 (11.2)    0.86
  intron1 G/A     AG         387       51 (13.2)           Leu125Val        CG         395       42 (10.6)    
                  GG         250       25 (10)                              GG         222       27 (12.2)    
  **CETP**        AA         205       18 (8.8)     0.39   **PECAM1**       AA         200       25 (12.5)    0.82
  -629C/A         AC         400       50 (12.5)           Ser563Asn        AG         386       42 (10.9)    
                  CC         197       21 (10.7)                            GG         214       22 (10.3)    
  **COMT**        AA         231       17 (7.4)     0.06   **PON1**         AA         396       36 (9.1)     0.09
  Val158Met       AG         358       43 (12)             Gln192Arg        AG         337       47 (14)      
                  GG         187       27 (14.4)                            GG         66        6 (9.1)      
  **CX3CR1**      CC         410       43 (10.5)    0.54   **PON2**         CC         464       56 (12.1)    0.43
  Ile249Val       CT         336       40 (11.9)           Cys311Ser        CG         298       28 (9.4)     
                  TT         56        4 (7.1)                              GG         40        3 (7.5)      
  **CX3CR1**      AA         18        1 (5.6)      0.73   **PPARG**        CC         637       73 (11.5)    0.32
  Thr280Met       AG         223       26 (11.7)           Ala12Pro         CG         159       15 (9.4)     
                  GG         565       63 (11.2)                            GG         8         2 (25)       
  **CYP11B2**     CC         163       18 (11)      0.84   **PTGS2**        CC         15        2 (13.3)     0.94
  -344T/C         CT         352       42 (11.9)           -765G/C          CG         202       22 (10.9)    
                  TT         275       29 (10.6)                            GG         576       65 (11.3)    
  **CYP2C9**      AA         708       79 (11.2)    0.89   **RECQL2**       CC         66        11 (16.7)    0.18
  Leu359Ile       AC         56        6 (10.7)            Arg1367Cys       CT         326       39 (12)      
                  CC                                                        TT         412       39 (9.5)     
  **CYP2C9**      CC         589       63 (10.7)    0.83   **SELE**         CC         658       71 (10.8)    0.43
  Cys144Arg\*\*   CT         147       15 (10.2)           Leu554Phe        CT         137       18 (13.1)    
                  TT                                                        TT         7         0 (0)        
  **ENPP1**       AA         600       64 (10.7)    0.75   **SELE**         AA         740       82 (11.1)    0.89
  Gln121Lys       AC         192       24 (12.5)           Ser128Arg        AC         63        7 (11.1)     
                  CC         15        2 (13.3)                             CC         2         0 (0)        
  **ESR1**        CC         145       21 (14.5)    0.32   **SELP**         AA         646       71 (11)      0.48
  -401T/C         CT         421       41 (9.7)            Thr715Pro        AC         150       19 (12.7)    
                  TT         239       27 (11.3)                            CC         9         0 (0)        
  **F12**         CC         459       51 (11.1)    0.73   **TFPI**         AA                                
  46C/T           CT         283       32 (11.3)           Val264Met        AG         32        4 (12.5)     0.71
                  TT         49        7 (14.3)                             GG         758       84 (11.1)    
  **F13A1**       GG         443       44 (9.9)     0.23   **THBD**         AA                                
  Val34Leu        GT         296       39 (13.2)           -33G/A           AG         3         1 (33.3)     0.23
                  TT         41        7 (17.1)                             GG         801       89 (11.1)    
  **F2**          AA         1         0 (0)        0.93   **THBD**         AA         11        2 (18.2)     0.46
  G20210A\*       AG         23        2 (8.7)             Ala25Thr         AG         794       87 (11)      
                  GG         783       88 (11.2)                            GG                                
  **F5**          AA         1         0 (0)        0.26   **THBD**         CC         531       64 (12.1)    0.52
  Arg506Gln       AG         36        1 (2.8)             Ala455Val        CT         237       22 (9.3)     
                  GG         769       89 (11.6)                            TT         24        2 (8.3)      
  **F7**          AA         16        5 (31.3)     0.01   **THBS1**        AA         614       66 (10.8)    0.65
  Arg353Gln       AG         148       19 (12.8)           Asn700Ser        AG         177       23 (13)      
                  GG         629       63 (10)                              GG         14        1 (7.1)      
  **FGB**         AA         24        0 (0)        0.10   **THBS2**        GG         74        10 (13.5)    0.65
  -455A/G         AG         247       23 (9.3)            3\'UTR T/G\*     GT         250       25 (10)      
                  GG         533       67 (12.6)                            TT         466       53 (11.4)    
  **GJA4**        CC         401       36 (9)       0.14   **THBS4**        CC         49        6 (12.2)     0.53
  C1019T          CT         313       38 (12.1)           Ala387Pro        CG         268       34 (12.7)    
                  TT         78        13 (16.7)                            GG         486       49 (10.1)    
  **GP1BA**       CC         13        1 (7.7)      0.87   **THPO**         AA         187       25 (13.4)    0.52
  -5T/C           CT         168       21 (12.5)           A5713G           AG         374       40 (10.7)    
                  TT         597       66 (11.1)                            GG         241       24 (10)      
  **GRL**         AA         756       83 (11)      0.68   **TLR4**         AA         702       85 (12.1)    0.10
  Asn363Ser       AG         47        6 (12.8)            Gly299Asp        AG         88        4 (4.6)      
                  GG                                                        GG         1         0 (0)        
  **HFE**         AA         3         0 (0)        0.04   **TNF**          AA         24        4 (16.7)     0.43
  Cys282Tyr       AG         96        18 (18.8)           -308G/A          AG         784       86 (11)      
                  GG         703       70 (10)                              GG                                
  **HTR2A**       CC         286       25 (8.7)     0.13   **TNFRSF1A**     AA         17        0 (0)        0.29
  Ser102Ser       CT         363       49 (13.5)           Arg92Gln         AG         189       19 (10.1)    
                  TT         134       16 (11.9)                            GG         597       71 (11.9)    
  **9p21**        GG         114       15 (13.2)    0.33   **9p21**         AA         175       23 (13.1)    0.28
  rs10116277      GT         365       41 (11.2)           Rs10757274       AG         375       44 (11.7)    
                  TT         243       20 (8.2)                             GG         226       19 (8.4)     
  **9p21**        CC         118       11 (9.3)     0.24                                                      
  Rs1333040       CT         332       44 (13.3)           **9p21**         AA         146       17 (11.6)    0.35
                  TT         306       28 (9.2)            Rs2383206        AG         375       46 (12.3)    
  **9p21**        AA         78        8 (10.3)     0.25                    GG         249       21 (8.4)     
  Rs2383207\*\*   AG         366       46 (12.6)                                                              
                  GG         268       22 (8.2)                                                               

\*HWE deviation (P \< 0.05); \*\*HWE deviation (P \< 0.01)

Of the 6 positive associations described above, 2 remained significant following Cox regression adjustment for traditional cardiac risk factors including age, sex, hypertension, diabetes, congestive heart failure, and ACS type, as well as treatment-related factors. Of these covariates, age (P \< 0.0001), diabetes (P \< 0.0001), and lack of revascularization (P \< 0.01) had the most significant associations with mortality when modeled independent of genotype. The G allele of *IRS1*was related to longer survival, with adjusted hazard ratios of 0.08 (0.02, 0.84) for A/G, and 0.23 (0.05, 0.99) for G/G, respectively. In addition, the *ICAM1*association remained significant, only for A/G heterozygotes (0.53; 95% CI: 0.33, 0.84), with the reference genotype being A/A.

In order to further explore the data for potential weak associations not quite meeting the P \< 0.05 significance threshold due to suboptimal power, we performed a simulation analysis as described above, to supplement visual inspection of the Q-Q plot (Figure [1](#F1){ref-type="fig"}), which was not precisely linear. The mean difference that we observed was -0.065 for all 89 genetic variables (Figure [2](#F2){ref-type="fig"}), indicating that some P values were lower than expected by chance alone. In addition to the 6 associations described above, 10 additional genetic variants had P values of 0.1 or lower. Upon removal of these 16 positive associations (P \< 0.1), the mean difference converged to zero in the remaining 73 genetic variables (Figure [2](#F2){ref-type="fig"}), suggesting no probable association with mortality.

![**Q-Q plot of Kaplan-Meier P values for 89 genetic variants**. Observed log-rank P values for individual Kaplan-Meier analyses are plotted against random expectations under the null hypothesis of no effect.](1471-2350-9-66-1){#F1}

![**Mean P value differences (observed-random) in 50,000 simulations**. The right panel shows a skewed distribution of simulated random minus actual Kaplan-Meier log-rank P values (N = 89), indicating that observed P values collectively were lower than expected. With the removal of 16 positive associations (P \< 0.1), the remaining genetic variables closely approximated a random distribution, as shown in the left panel.](1471-2350-9-66-2){#F2}

Discussion
==========

Of the 89 genetic variants tested, we found strong statistical evidence of an association for only one, the *IRS1*Gly972Arg polymorphism, although it was based upon a small number of deaths in individuals who would already have been considered at high risk for mortality. Thus, we can not unequivocally implicate any of the genetic variants included in this study as a prognostic factor following ACS, including those in the 9p21 region. The possible explanations for our essentially null findings include inadequate power for survival analysis, given that mortality following ACS occurred in only 11.1% of our case sample, or that the genetic variants included in our study have no impact on post-MI prognosis.

With respect to statistical power, we have presented evidence that at least 73 of the gene variants seemed identical to random variables, and therefore, our data provide no support for the hypothesis that testing these particular variants in larger samples would likely yield positive results. It is unlikely that mortality in direct relation to any of these gene variants is a common occurrence following ACS. Furthermore, as shown in Table [1](#T1){ref-type="table"}, conventional cardiac risk factors such as advanced age and diabetes appear to be dominant factors in determining prognosis, and therefore, it may be challenging to demonstrate an independent genetic effect on mortality without sample sizes far in excess of 800 patients, particularly if genetic or pharmacogenetic interactions are explored.

However, given the limitations of our sample size, we were unable to exclude modest effects in association with the remaining 16 gene variants, 6 of which had nominally statistically significant associations with post-ACS mortality. Of these, only 2 remained significant after adjustment for traditional cardiac risk factors, with *ACE1*, *APOA1*, *F7, and HFE*having no independent association. As might have been expected, known confounding variables such as age, sex, and comorbidity proved to be important predictors of mortality in the Cox regression models. In addition, *APOA1*was related to a small number of deaths, and the association of the I/I genotype of *ACE1*would seem paradoxical, given that the D/D genotype has been postulated as a cardiac risk factor in most studies.

As with *ACE1*, the association of the *F7*glutamine allele would also have to have been considered paradoxical, *a priori*, given that this allele was originally reported to be protective against the occurrence of myocardial infarction, and it correlates with lower *F7*activity and hence lesser coagulability. However, it was the relatively rare A/A genotype of *F7*that conferred the greatest risk of mortality in our population of ACS patients, which is consistent with the hypothesis that rare variants may have relatively large genetic effects. Interestingly, all 5 deceased individuals with the A/A genotype had NSTEMI, which is improbable (P = 0.005) given that only 35% of the cases had this manifestation of ACS, and 4 of 5 had either prior MI (N = 3) or a history of revascularization (N = 1). Thus, further study of the *F7*allele is warranted, especially in NSTEMI patients.

In contrast, it is possible to postulate a plausible cardiovascular risk mechanism for the hemochromatosis-associated A allele. Heterozygotes for the A allele, on average, have relatively increased total body iron stores.\[[@B19],[@B20]\] In addition, some data indicate that iron excess may lead to free radical formation and thereby confer risk of myocardial infarction.\[[@B21]\] However, a limitation of our study is a lack of phenotypic data on serum iron stores (e.g., ferritin or serum iron levels). In addition, the existing literature on *HFE*does not show a consistent association with cardiac disease, and the allele was not even marginally associated with the occurrence of ACS in our study population.\[[@B5]\]

In judging the likely validity of the remaining 2 genetic associations that remained statistically significant despite extensive adjustment for comorbidity and treatment variables, one must consider the magnitude of the risk, the numbers of deaths observed, as well as the relationship of the genotypic risk pattern in the context of the functional biology of each particular gene.\[[@B22]\]

The *ICAM1*Lys469Glu association was related to relatively increased mortality (15.9%) among individuals with the A/A genotype (lysine homozygotes). This is higher than the overall 11.1% mortality rate in the cohort, and there were 43 deaths among individuals with this frequent (34.0%) genotypic class. However, it is the 469Glu allele that is postulated to have deleterious pro-inflammatory effects,\[[@B23]\] and therefore, no biological mechanism for this association is immediately obvious.

The strongest genetic association was detected for the rare A allele (coding for arginine) of the *IRS1*Gly972Arg polymorphism. Even a Bonferroni-corrected P value for this association had borderline (P \< 0.1) study-wide significance. IRS1 is activated as an intracellular signal transducer, in adipocytes and skeletal muscle cells, when its tyrosine residues are phosphorylated by the insulin-bound insulin receptor, the function of which is inhibited *in vitro*by the Arg972 residue, leading to decreased glucose uptake.\[[@B24],[@B25]\] Baroni *et al*(1999) reported the A allele as a risk factor for coronary artery disease (18.9% vs. 6.8%),\[[@B25]\] and there have been inconsistent reports of this polymorphism being more prevalent among diabetics,\[[@B26],[@B27]\] perhaps causing defective phosphatidylinositol 3-kinase interaction, peripheral insulin resistance, and impaired insulin secretion. In addition, Harrap *et al*reported a subthreshold linkage peak containing *IRS1*in a genome-wide scan of 61 sibling pairs with acute coronary syndrome, adding to interest in the *IRS1*locus as a cardiac candidate gene.\[[@B28]\] However, IRS1 was not associated with the primary occurrence of ACS in our previous case-control analysis.\[[@B5]\] Moreover, due to the rarity of arginine homozygous genotype, the association in our study population was largely based on the deaths of 2 individuals among the 3 with the A/A genotype. Accordingly, further prognostic study of this rare genotype is warranted in larger populations of ACS patients, particularly those with diabetes.

In 3 of the 6 nominally significant bivariate associations described above (*ACE*, *F7*, *ICAM1*), the allele hypothesized to be protective against ACS occurrence was associated with early death following ACS, creating an apparent paradox. These may be false positive associations. However, such apparently paradoxical, but well-validated, associations have been observed in prognostic studies (e.g., the association between active smoking and lower mortality following ACS).\[[@B29]\] One theoretical explanation could be survivorship bias, meaning that most individuals with the genetic risk factor never survive the initial cardiac event, and that the remaining individuals are those with the best prognosis. Although potentially interesting, this hypothesis is difficult to investigate except prospectively, with ascertainment prior to the initial cardiac event.

Conclusion
==========

In summary, our study has provided no uneqivocal support for the hypothesis that any of 89 genetic variants in 72 genetic loci contribute to death following ACS. However, in the context of multiple genetic comparisons, and necessarily modest numbers of deaths in a cohort of 811 individuals with ACS, it is challenging to interpret P values of borderline study-wide significance. Thus, we can not exclude relatively modest survival effects in the 16 gene variants with P \< 0.1 (Table [3](#T3){ref-type="table"}). Further study of these variants would be warranted, and meta-analysis would augment power to detect weak effects. In addition, given the recent success of the whole genome association approach in the identification of 9p21 and other promising cardiovascular candidate genes, it is plausible that this approach may have similar success in identifying genetic risk factors for prognosis following ACS.
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